Vontobel Holding’s Regenxbio RGNX Stock Holding History

Vontobel Holding’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-46,639	Closed	-$1.23M	–	1117
2022 Q3	$1.23M	Sell	46,639 -2,668	-5%	-$79.2K	0.01%	500
2022 Q2	$1.22M	Buy	+49,307	New	+$1.23M	0.01%	496
2021 Q4	–	Sell	-10,000	Closed	-$419K	–	1188
2021 Q3	$419K	Hold	10,000	–	–	﹤0.01%	851
2021 Q2	$389K	Hold	10,000	–	–	﹤0.01%	837
2021 Q1	$341K	Hold	10,000	–	–	﹤0.01%	763
2020 Q4	$454K	Buy	+10,000	New	+$349K	﹤0.01%	678

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vontobel Holding's RGNX Position: Q4 2022 in Review

Vontobel Holding sold out of Regenxbio (RGNX) in Q4 2022, closing a stake of 46,639 shares — an estimated $1.23M sold.

Vontobel Holding first reported a position in RGNX in Q4 2020 and held it in 6 quarters. The position peaked at $1.23M in Q3 2022. 180 funds tracked by Wall St. Rank hold RGNX as of Q4 2022.

Vontobel Holding reported no remaining Regenxbio position as of Q4 2022 after selling out during the quarter.
Vontobel Holding sold 46,639 Regenxbio shares in Q4 2022, an estimated $1.23M.
Vontobel Holding first reported a position in Regenxbio in Q4 2020 and held it in 6 quarters.
Vontobel Holding's Regenxbio position peaked at $1.23M in Q3 2022.
180 funds tracked by Wall St. Rank held Regenxbio as of Q4 2022.

Based on Vontobel Holding's 13F filing for Q4 2022, filed 14 Feb 2023.